Suggested remit - To appraise the clinical and cost effectiveness of crizanlizumab within its marketing authorisation for preventing sickle cell crises in sickle cell disease
 
Status Proposed
Process STA 2018
ID number 1406

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
22 March 2019 - 19 April 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance